Search Results
262 Results for 'Therapeutics & Vaccines'
PAGE 8 OF 11
Technology
Analogs of Diptoindonesin G for Breast Cancer Drug Development
The natural product diptoindonesin G (Dip G) was first isolated in 2009 from the tree bark of Hopea mengarawan. It has shown antiproliferation effects in murine leukemia as well as immunosuppressant a...
Learn More
Learn More
Wei Xu, Weiping Tang, Jitian Liu, Jill Kolesar | P170010US02
Technology
Enhanced HIV Treatments: Boronic Acid Group Improves Drug Potency
HIV infection, AIDS and AIDS-related complex (ARC) remain serious and ongoing diseases compromising the human immune system. Protease inhibitors, which interfere with the replication cycle of HIV, are...
Learn More
Learn More
Ronald Raines, Ian Windsor, Michael Palte, John Lukesh | P140376US02
Technology
Treatment of Fragile X Syndrome Using Nutlin-3
Fragile X Syndrome (FXS) is the most common form of inherited intellectual disability, affecting 1 in 4,000 males and 1 in 6,000 females. It is characterized by severe learning problems, developmental...
Learn More
Learn More
Xinyu Zhao, Yue Li | P150380US02
Technology
Better Living Through Peptides; Improved Approach to HIV Therapy
Human immunodeficiency virus (HIV) affects over 1.2 million Americans each year, with approximately 50,000 new infections per year. Current treatment includes HIV combination regimens comprising rever...
Learn More
Learn More
Samuel Gellman, William Horne, Lisa Johnson | P08414US03
Technology
Retinoic Acid: A New Treatment for Sleep Apnea and Hypopnea
Sleep apnea affects an estimated 18 million American adults annually. People with sleep apnea can develop conditions such as systemic and pulmonary hypertension, metabolic syndrome, insomnia, neuro-in...
Learn More
Learn More
Tracy Baker, Gordon Mitchell, Daryl Fields | P150330US02
Technology
Nylon-3 Polymers Active Against Clostridium Difficile
Clostridium difficile is a Gram-positive, endospore-forming anaerobe that causes life-threatening intestinal infections. These infections result in more than 14,000 deaths and billions of dollars in h...
Learn More
Learn More
Samuel Gellman, Runhui Liu, Bernard Weisblum, Shonna McBride | P150214US02
Technology
New and More Potent UGM Inhibitors for Treating Tuberculosis, Other Microbial Infections
Mycobacterium tuberculosis, the causative agent of tuberculosis, is responsible for eight million human infections and two million deaths worldwide each year. M. tuberculosis infections can be treated...
Learn More
Learn More
Laura Kiessling, Valerie Winton, Alexander Justen | P160093US02
Technology
Peptides to Treat Alzheimer’s Disease
Amyloid-beta (Aβ) peptides play a crucial role in Alzheimer’s disease – they are a main component of the toxic amyloid plaques found in patients’ brains. Aβ is so dangerous because it can aggr...
Learn More
Learn More
Regina Murphy, Jeffrey Johnson, Patricia Cho, Xiaomeng Lu | P140391US02
Technology
Skin Whitening Agent(s)
The global cosmetics industry is a $460 billion dollar market with the skin whitening sector valued at $381 million in 2014. This growing market is projected to increase at a CAGR of 11.7%, reaching $...
Learn More
Learn More
Cheng-chen Huang, Aaron Monte | T140007WO01
Technology
Warfarin Promoter
Warfarin is a “first-generation” anticoagulant that has been widely used as a multiple feeding rodenticide for more than 60 years. The prolonged use of warfarin as a rodenticide has, according to ...
Learn More
Learn More
David Lewis, Michael Caldwell | T100001US02
Technology
Novel Subtype of Botulinum Toxin for Prolonged Effectiveness
Clostridium botulinum produces botulinum neurotoxin (BoNT), which can cause debilitating disease but also is used to treat disorders like chronic headache, spastic muscles and strabismus.
Several di...
Learn More
Learn More
Eric Johnson, Mark Jacobson, Guangyun Lin, William Tepp, Raymond Stevens, Jerome Dupuy, Paul Stenmark | P09050US02
Technology
New Broad-Spectrum Antibiotics
The rise of antibiotic-resistant bacteria represents a potential health crisis. Some antibiotics (e.g., quinolones and fluoroquinolones) are losing their effectiveness while others simply don’t ...
Learn More
Learn More
Douglas Weibel, Katherine Hurley, Katherine Faulkner | P140321US02
Technology
Long-Lasting, Non-Narcotic Protein for Treatment of Acute or Chronic Pain
Millions of people in the U.S. suffer from chronic pain each year. Narcotic-based medications commonly are given for pain relief, but they are not always effective and can lead to addiction.
Botulinu...
Learn More
Learn More
Eric Johnson, Sabine Pellett, William Tepp, Tony Yaksh, Marc Marino, Qinghao Xu | P130093US02
Technology
Increasing Red Blood Cell Production
Maintaining an adequate supply of oxygen to tissue is necessary for survival. The oxygen-carrying capacity of blood is governed by the concentration of red blood cells (erythrocytes). It is critical t...
Learn More
Learn More
Emery Bresnick, Yoon A Kang, Skye McIver | P130326US02
Technology
Treating Iron Overload with Block Copolymers
Iron overload or hemochromatosis is a disease marked by an accumulation of iron in the blood. It typically occurs in subjects (e.g., anemia patients) receiving chronic infusions of red blood cells. Th...
Learn More
Learn More
May Xiong, Zhi Liu, Yan Wang | P140395US02
Technology
Generic Drug to Treat and Prevent Macular Degenerative Diseases
More than 30 million people suffer from age-related macular degeneration (AMD), the most common cause of permanent vision loss among older adults. Few treatment options are available for AMD, or for j...
Learn More
Learn More
Aparna Lakkaraju, Kimberly Toops, Li Xuan Tan | P140282US02
Technology
Use of Peptides of Syndecan-1 to Inhibit Angiogenesis
Syndecans, a highly conserved family of four transmembrane heparan sulfate proteoglycans, bind a variety of extracellular matrix ligands, including fibronectin, laminin and vitronectin. Syndecan-1 ser...
Learn More
Learn More
Alan Rapraeger, DeannaLee Beauvais | P06390US02
Technology
Treating Absence Epilepsy with Ganaxolone
Absence epilepsy (formerly known as ‘petit mal epilepsy’) afflicts thousands of people worldwide, many of them children. It is characterized by nonconvulsive seizures, loss of consciousness, glass...
Learn More
Learn More
Mathew Jones, Chiara Cirelli, Kile Mangan, Aaron Nelson | P140051US02
Technology
Hormone Analogs for Treating Hypoparathyroidism
The proper functioning of cells depends on information traveling from the extracellular environment to the cytoplasm. Most signals must be conveyed via proteins that span the cellular membrane. Many o...
Learn More
Learn More
Samuel Gellman, Ross Cheloha, Thomas Gardella | P130312US03
Technology
Non-Natural Peptides for Treating Diabetes
Diabetes mellitus continues to be a chronic public health issue despite the availability of injectable insulin since the 1920s. Finding alternative treatments is the subject of intense research. In re...
Learn More
Learn More
Samuel Gellman, Lisa Johnson, Alan Attie, Alan Saghatelian, Mark Keller | P130310US02
Technology
Novel Subtype of Botulinum Toxin for Pharmaceutical Use
Clostridium botulinum produces botulinum neurotoxin (BoNT), which can cause debilitating disease but also is used to treat disorders like chronic headache, spastic muscles and strabismus.
The bacteri...
Learn More
Learn More
Eric Johnson, Kristin Marshall, Sabine Pellett, Marite Bradshaw | P06269US
Technology
Influenza Variant Grows Well in CHO Cells
Vaccines against influenza and other viruses can be grown in Chinese Hamster Ovary (CHO) cells. Problematically, an influenza virus that is made by combining H1N1 and PR8 strains, and that is recommen...
Learn More
Learn More
Yoshihiro Kawaoka, Makoto Ozawa | P100246US02
Technology
Neuraminidase-Deficient Live Influenza Vaccine
Influenza infects up to 20 percent of the world’s population every year, causing 500,000 deaths and costing tens of billions of dollars in medical expenses. Influenza A virus, which causes pandemics...
Learn More
Learn More
Yoshihiro Kawaoka, Masato Hatta | P07044US
Technology
Treating Fungal Infections with New Forazoline Compounds
Fungal infections range in severity from common athlete’s foot to life-threatening illness. Treatment can be very expensive. The cost of treating systemic Candida yeast infections exceeds $31,000 pe...
Learn More
Learn More
Timothy Bugni, Thomas Wyche, David Andes, Douglas Braun | P130274US02
Technology
Treating Staph Infections, Toxic Shock Syndrome by Disrupting Bacteria Quorum Sensing
‘Staph’ infections, particularly by Staphylococcus aureus strains, can cause skin ailments and more serious conditions like heart valve inflammation and toxic shock syndrome. These strains...
Learn More
Learn More
Helen Blackwell, Danielle Wittenwyler, Yiftah Tal Gan | P130070US02